BRIEF—ProQR and Lilly expand collab into new therapy areas

Eli Lilly and ProQR Therapeutics have expanded their licensing and collaboration agreement focused on the discovery, development and commercialization of new genetic medicines.

The companies will explore further applications of ProQR’s Axiomer platform with the goal of discovering new treatments, focusing on targets in the central nervous system and peripheral nervous system.

The new deal builds on the original agreement, reached in September 2021, targeting the liver and nervous system.

Lilly will pay $75 million, including an equity investment, and will gain an option on further expansion for the sum of $50 million.

In total, including the original deal, ProQR is eligible to receive up to around $3.75 billion in research, development and commercialization milestones, as well as tiered royalties on sales.